We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-0.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$471M
AUM Growth
-$63.9M
Cap. Flow
-$5.68M
Cap. Flow %
-1.2%
Top 10 Hldgs %
58.75%
Holding
54
New
6
Increased
11
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$25.5M
2
DNA icon
Ginkgo Bioworks
DNA
+$11M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$7.95M
4
MRUS
Merus
MRUS
+$6.15M
5
HYPR icon
Hyperfine
HYPR
+$6.04M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$7.76M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$7.17M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.98M
4
CLDX icon
Celldex Therapeutics
CLDX
+$6.14M
5
SMLR
Semler Scientific
SMLR
+$6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
51
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-1,220
Closed -$1.2M
SIOX
52
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-955,000
Closed -$2.07M
FMTX
53
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-182,950
Closed -$4.24M
ADMS
54
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-1,460,000
Closed -$7.17M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2021 Portfolio in Review

As of Q4 2021, Opaleye Management held 54 positions worth $471M, down 12% from $535M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q4 2021 filing shows 6 new, 11 increased, 10 reduced and 15 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M. The largest sale was BridgeBio Pharma, an estimated $7.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q4 2021 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $7.95M increase.
  • Opaleye Management's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $7.76M.
  • Opaleye Management fully exited Adamas Pharmaceuticals in Q4 2021, selling an estimated $7.17M.
  • Opaleye Management's ten largest holdings make up 59% of its $471M portfolio in Q4 2021.
  • Opaleye Management opened 6 new positions and closed 15 in Q4 2021.
  • Opaleye Management's portfolio value fell 12% quarter-over-quarter to $471M.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.